further highlight the immuno-onocolgy opportunity. Beyond bladder cancer data at ASCO, potential in other tumours and the data in combination with Avastin, if positive, have the potential to drive further upside to PD-L I forecasts, although on the 1Q14 call Roche seemed more cautious than previously